SNK Cell Therapy
Oncological and Neurodegenerative Diseases
Phase 1Active
Key Facts
About NKGEN Biotech
NKGen Biotech, founded in 2017 and based in Santa Ana, California, is pioneering the development of 'super-activated' natural killer (NK) cell immunotherapies. The company's core technology, the SNK platform, is designed to enhance the body's innate immune cells to target and eliminate diseased cells, with applications in both oncology and neurodegeneration. As a private, clinical-stage company, it is advancing a pipeline of cell therapies through clinical trials, positioning itself in the competitive but high-potential cell and gene therapy sector. Its leadership team combines expertise in immunology, oncology, and neurodegenerative diseases.
View full company profile